Literature DB >> 29473600

Osteoporosis for the practicing neurologist.

Micol S Rothman1, Sterling G West1, Michael T McDermott1.   

Abstract

Osteoporosis is a common condition of impaired bone strength leading to fractures. A targeted history, physical exam, and blood work can help elucidate potentially reversible causes of low bone mass. In the neurology office, particular attention should be paid to the patient on glucocorticoids or antiepileptic medications, as these have distinct detrimental effects on bone. Patients can be risk-stratified by using the FRAX calculator, a tool that can help determine whether the patient is at sufficient risk of fracture to warrant pharmacologic therapy. Nonpharmacologic treatments such as calcium, vitamin D, and exercise should be discussed with the patient. The cornerstone of pharmacologic therapy has been treatment with bisphosphonates, but newer medications are available as well for the high-risk patient.

Entities:  

Year:  2014        PMID: 29473600      PMCID: PMC5765589          DOI: 10.1212/01.CPJ.0000437349.39987.fa

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  33 in total

1.  Bone mineral density in adult patients treated with various antiepileptic drugs.

Authors:  Simona Alexandra Beniczky; Janina Viken; Lars Thorbjørn Jensen; Noémi Becser Andersen
Journal:  Seizure       Date:  2012-04-26       Impact factor: 3.184

Review 2.  Pathogenesis of osteoporosis: concepts, conflicts, and prospects.

Authors:  Lawrence G Raisz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.

Authors:  Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver
Journal:  J Clin Endocrinol Metab       Date:  2011-06-06       Impact factor: 5.958

4.  Falls and fractures in patients chronically treated with antiepileptic drugs.

Authors:  Baemisla Shiek Ahmad; Keith David Hill; Terence John O'Brien; Alexandra Gorelik; Natalie Habib; John Dennis Wark
Journal:  Neurology       Date:  2012-06-13       Impact factor: 9.910

5.  Alendronate for the treatment of osteoporosis in men.

Authors:  E Orwoll; M Ettinger; S Weiss; P Miller; D Kendler; J Graham; S Adami; K Weber; R Lorenc; P Pietschmann; K Vandormael; A Lombardi
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

6.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

7.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

8.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

9.  The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

Authors:  E S Orwoll; W H Scheele; S Paul; S Adami; U Syversen; A Diez-Perez; J M Kaufman; A D Clancy; G A Gaich
Journal:  J Bone Miner Res       Date:  2003-01       Impact factor: 6.741

Review 10.  Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis.

Authors:  Mark J Bolland; Alison Avenell; John A Baron; Andrew Grey; Graeme S MacLennan; Greg D Gamble; Ian R Reid
Journal:  BMJ       Date:  2010-07-29
View more
  1 in total

1.  Osteoporosis for the practicing neurologist.

Authors:  Khichar Shubhakaran; Rekha Jakhar Khichar
Journal:  Neurol Clin Pract       Date:  2014-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.